

miR-218 inhibits glucose metabolism in non-small cell lung cancer via the NF- κ B signaling pathway

WENXIAN TIAN^{1*}, XIANGFEI YUAN^{2*}, YONGNA SONG¹, JIANXIA ZHAI¹,
HAIXIA WEI¹, LINNA WANG¹, DAN LI¹ and QIUSHENG CHEN¹

¹Department of Pulmonary and Critical Care Medicine, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450000; ²Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and Institute of Traditional Chinese and Western Medicine, Institute of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin 300100, P.R. China

Received May 20, 2019; Accepted March 3, 2020

DOI: 10.3892/etm.2020.9538

Abstract. High glucose metabolism is recognized as one of the hallmarks of cancer and increased expression levels of several key factors involved in glucose metabolism have been reported in non-small cell lung cancer (NSCLC). Previous studies showed that microRNA (miR)-218 is reduced in NSCLC, but its function in glucose metabolism in NSCLC is not fully understood. The present study aimed to investigate the effect of miR-218 on glucose metabolism in NSCLC cell lines and the underlying molecular mechanism. The present results suggested that miR-218 reduced glucose consumption, the mechanism of glycolysis and activity in the pentose phosphate pathway. In addition, glucose transporter 1 (GLUT1) was identified to be a direct target of miR-218, while overexpression of GLUT1 did not abolish the effect of miR-218 on glucose metabolism. The present results indicated that phosphorylation of NF- κ B p65 was significantly decreased by miR-218 in NSCLC cells and that activation of NF- κ B led to the inhibition of miR-218 regulation of glucose metabolism. In conclusion, the present results suggested that miR-218 downregulated glucose metabolism in NSCLC not only by directly targeting GLUT1, but also via the NF- κ B signaling pathway.

Introduction

Lung cancer is a cause of cancer mortality in patients. In total, >two-thirds of all lung cancer types are a part of the subtype

of non-small cell lung cancer (NSCLC) (1). In NSCLC, high expression levels of glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) facilitate glucose uptake and are the initial steps of glucose metabolism (2,3). Previous studies have revealed high glucose metabolism as one of the hallmarks of numerous cancers, in which glycolysis provides ATP rapidly and the pentose phosphate pathway (PPP) generates pentose phosphates for ribonucleotide synthesis and NADPH to meet the demand of rapid proliferation (4-6). Previous studies have reported that inhibition of glycolysis and PPP influences the growth of NSCLC cells (7-9).

MicroRNAs (miRNA/miRs) are non-coding RNA molecules of 19-25 nucleotides that negatively regulate gene expression by interacting with 3'untranslated regions (3'UTRs) of the target genes (10). Several miRNAs have been reported to be associated with the progression of NSCLC, serving as either oncogenes or tumor suppressors (11-13). Previous studies have suggested that miR-218 expression levels are reduced in multiple cancer types (14,15), including NSCLC (16,17). Previous studies have also revealed that miR-218 can regulate the metastasis and chemosensitivity of NSCLC (18-20). GLUT1 is indicated to be a direct target of miR-218 in bladder cancer (21), however the function of miR-218 in glucose metabolism in NSCLC remains unclear and the underlying molecular mechanism is still unknown.

The present study aimed to investigate the effect of miR-218 on the glycolysis and PPP pathways and assess the impact of miR-218 on the expression levels of related key enzymes in NSCLC cell lines. Furthermore, the potential mechanisms associated with these effects were investigated.

Materials and methods

Cell culture and treatment. NCI-H23 and A549 human NSCLC cells were purchased from Shanghai Cell Biology Institute of Chinese Academy of Sciences. Cells were maintained in RPMI-1640 medium (cat. no. 22400089; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (cat. no. 10437028; Gibco; Thermo Fisher Scientific, Inc.). NCI-H23 and A549 cells (2x10⁵ cells/well) were seeded into 6-well plates and transiently transfected with 50 nM

Correspondence to: Dr Qiusheng Chen, Department of Pulmonary and Critical Care Medicine, Zhengzhou Central Hospital Affiliated to Zhengzhou University, 16 Tongbai North Road, Zhengzhou, Henan 450000, P.R. China
E-mail: chen126000@sohu.com

*Contributed equally

Key words: non-small cell lung cancer, microRNA-218, glycolysis, pentose phosphate pathway, NF- κ B

miR-218 mimics (cat. no. B02003) or mimics control (cat. no. B04002; both Shanghai GenePharma Co., Ltd.) using Lipofectamine 2000 reagent (cat. no. 11668019; Thermo Fisher Scientific, Inc.). After 48 h of transfection the subsequent experimentations were performed.

Preparation of lentivirus and establishment of stable cell lines. The GLUT1 gene sequence was amplified from the cDNA of A549 cell line by PCR and the following primers: 5'-CCGTCTAGAGCCACCATGGAGCCCAGCAGCAAGAAG-3' (forward); 5'-GGCGGATCCTCACACTTGGGAATCAGCCC-3' (reverse) were inserted into the plasmid pCDH1-CMV-MSC-EF1-Puro (System Biosciences) at the *Xba*I and *Bam*HI sites. The acquired vector was termed 'pCDH-GLUT1'. A sequence containing the U6 promoter and a template of inhibitor of κ B (IkB α) short hairpin RNA (shRNA), shown in Table SI, were synthesized, inserted in pCDH-GLUT1 (30 ng/ μ l) by *Bam*HI and *Not*I restriction enzymes (New England Biolabs, Ltd.), and the acquired vector was termed 'pCDH-GLUT1-shIkB α '. The package method of lentivirus preparation was performed as previously described (22). A549 cells were transfected with lentivirus for 48 h and with 30 μ g/ml puromycin (cat. no. P8230; Beijing Solarbio Science & Technology Co., Ltd.) for 2 weeks.

Total RNA isolation and reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from cells or tissue samples using TRIzol[®] reagent (cat. no. 15596026; Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Total RNA (1 μ g) was reverse transcribed into cDNA using the RevertAid First Strand cDNA Synthesis kit (cat. no. K1622; Thermo Fisher Scientific, Inc.) at 42°C, according to the manufacturer's protocol. qPCR was subsequently performed using the SYBR[®] Premix Ex Taq[™] kit (cat. no. RR420L; Takara Biotechnology Co., Ltd.). The thermocycling protocol for the reaction was as follows: Initial denaturation at 95°C for 10 min; 40 cycles of 95°C for 15 sec and 60°C for 1 min. Gene expression was quantified using the 2^{- $\Delta\Delta$ C_q} method (23). The primers used in the research were as follows: miR-218 forward, 5'-TTGCGGATGGTTCCGTCAAGCA-3'; miR-218 reverse, 5'-ATCCAGTGCAGGGTCCGAGG-3'; U6 forward, 5'-CGCTTCGGCAGCACATATAC-3'; U6 reverse, 5'-AAAATATGGAACGCTTCACGA-3'. U6 was used as a reference gene.

Measurement of glucose, lactate and NADPH/NADP⁺. NCI-H23 and A549 cells were seeded into 6-well plates (2 \times 10⁵ cells/well), followed by culturing till 90% confluence was reached, replaced with fresh medium and then cultured for 6 h at 37°C. The supernatant was collected, in which the contents of glucose and lactate were determined by using a glucose assay kit and a lactic acid assay kit produced by Nanjing Jiancheng Bioengineering Institute Co., Ltd. (cat. no. F006-1-1 and cat. no. A019-2-1). Glucose consumption was calculated by subtracting the final concentration from the initial concentration of the medium. The NADPH/NADP⁺ ratios in cellular lysates were determined using an NADP/NADPH assay kit (cat. no. ab65349; Abcam) at an optical density of 450 nm. All these tests were performed according to the manufacturer's protocol.

Protein extraction and western blotting. Expression levels of target proteins and GLUT1 membrane localization were examined as previously described (24). Whole-cell proteins and membrane proteins were extracted using RIPA lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.) and a membrane protein extraction kit (Sangon Biotech Co., Ltd.), respectively. Protein concentration was quantified by bicinchoninic acid protein assay kit (cat. no. PC0020; Beijing Solarbio Science & Technology Co., Ltd.) and proteins (40 μ g per lane) were separated in 12% polyacrylamide gel. After electrophoresis, the proteins were transferred into PVDF membrane (cat. no. IPVH00010; EMD Millipore), followed by blocking with 5% BSA (cat. no. A8020; Beijing Solarbio Science & Technology Co., Ltd.) in TBST (with 0.1% Tween-20) at room temperature for 3 h and then incubating with primary antibodies (1:1,000) at 4°C overnight. Next, the membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse (cat. no. SE12; 1:2,000; Beijing Solarbio Science & Technology Co., Ltd.) or anti-rabbit (cat. no. SE13; 1:2,000; Beijing Solarbio Science & Technology Co., Ltd.) secondary antibodies for 1 h at room temperature. The protein bands were visualized by BioVision ECL western blotting substrate kit (cat. no. K820-500; BioVision, Inc.). ImageJ software (version 1.5; National Institutes of Health) was used to analyze the intensities of the band signals obtained. The antibodies of GLUT1 (cat. no. ab115730), HK2 (cat. no. ab104836), glucose-6-phosphate dehydrogenase (G6PD; cat. no. ab993), NF- κ B p65 (cat. no. ab32536), and phosphorylated (p)-NF- κ B p65 (cat. no. ab86299) were obtained from Abcam. The antibodies of phosphofructokinase-1 (PFK1; cat. no. sc-377346), ERK1/2 (cat. no. sc-514302), p-ERK1/2 (cat. no. sc-81492), JNK1/2 (cat. no. sc-137019) and p-JNK1/2 (cat. no. sc-293136) were obtained from Santa Cruz Biotechnology, Inc. The antibodies for Akt (cat. no. 9272) and p-Akt (cat. no. 4060) were produced by Cell Signaling Technology, Inc..

Luciferase reporter assay. The 3'UTRs of GLUT1, HK2, FPK1 and G6PD were synthesized and inserted into psiCHECK-2 plasmid (Promega Corporation) at the restriction enzyme sites of *Xho*I and *Not*I. Sequences are shown in Table SI. The acquired vectors were termed as 'psiGLUT1', 'psiHK2', 'psiFPK1' and 'psiG6PD'. Then cancer cells at a density of 4 \times 10⁵/well were seeded into 6-well plates and cotransfected with either 50 nm miR-218 mimics or miRNA negative control (NC) and 2 μ g above vectors, using Lipofectamine 2000 according to the manufacturer's protocol. The cells were lysed and then assayed for luciferase activity at 48 h post-transfection using a Dual-luciferase[®] reporter assay kit (Promega Corporation). The assays were repeated independently >3 times. Firefly luciferase was used as a reference for normalization.

Statistical analysis. All data were obtained from 3-5 independent experiments and are presented as mean \pm SD. Two-sided, unpaired Student's t-test was used for comparing between groups. One-way ANOVA was used to compare categorical variables. Significant differences between experimental groups were assessed using Bonferroni post hoc test. P<0.05 was considered to indicate a statistically significant difference. The analysis was performed using GraphPad Prism 5 (GraphPad Software Inc.).




Figure 1. miR-218 reduces glucose consumption and activities of glycolysis and pentose phosphate pathway. (A) Expression levels of miR-218 were measured in NCI-H23 and A549 cells after transfection with NC or miR-218 mimics, n=3. Then (B) glucose consumption, (C) lactate production and (D) ratio of NADPH to NADP⁺ were investigated, n=5. (E) Western blotting was performed to determine the protein expression levels of key enzymes involved in glucose metabolism, n=5. *P<0.05 and **P<0.01. Data are presented as mean \pm SD. NC, negative control; miR-218, microRNA-218; GLUT1, glucose transporter 1; HK2, hexokinase 2; PFK1, phosphofructokinase-1; G6PD, glucose-6-phosphate dehydrogenase.

Results

miR-218 reduces glucose consumption and activities of glycolysis and PPP. To study the effect of miR-218 on glucose metabolism in NSCLC cell lines, miR-218 mimics or NC were transfected into NCI-H23 and A549 cells. miR-218 expression levels were significantly increased in the two cell lines after transfected with mimics compared with the NC group (P<0.01; Fig. 1A). Then the levels of glucose and lactate in the supernatant, as well as the NADPH/NADP⁺ ratio in cellular lysates, were measured. Glucose uptake was significantly reduced by transfection with miR-218 mimics in both NSCLC cell lines (Fig. 1B), as well as lactate production, which represents the activity of glycolysis (Fig. 1C). Similarly, the ratio of NADPH, which is a product of PPP, to NADP⁺ in miR-218 mimic transfection group showed a significant decrease compared with the NC group (P<0.05; Fig. 1D). The present results indicated that miR-218 could decrease glucose uptake and the activities of glycolysis and PPP in NSCLC cells. In addition, the expression

levels of key enzymes involved in glucose uptake, glycolysis and PPP in the transfected NCI-H23 and A549 cells were investigated by western blotting. The present results suggested that GLUT1, HK2, PFK1 and G6PD expression levels were significantly decreased by miR-218 in both cell lines (Fig. 1E).

miR-218 inhibits glucose metabolism by downregulating GLUT1. To investigate whether miR-218 regulated the expression of GLUT1, HK2, PFK1 and G6PD directly, the 3'UTRs of these were inserted into luciferase reporter vectors. Then the luciferase reporter assay was used for detection after cotransfection with reporter vector and mimics or NC in A549 cells. The present results suggested a significant decrease in activity only by 3'UTRs of GLUT1 (Fig. 2A). Then A549-GLUT1, a cell line that overexpressed GLUT1 stably, was used to explore whether there are any other mechanisms involved in mediating glucose metabolism inhibition of miR-218 except for the down-regulation of GLUT1 directly and was identified by western blotting (Fig. 2B). The present results indicated that glucose




Figure 2. miR-218 inhibits glucose metabolism via downregulation of GLUT1. (A) A luciferase reporter assay was conducted to investigate whether key enzymes involved in glucose metabolism are direct targets of miR-218, $n=5$. (B) A549-GLUT1, a stable cell line that overexpressed GLUT1 was constructed and identified by western blotting. (C) Glucose consumption, (D) lactate production and (E) the ratio of NADPH to NADP⁺ were measured after transfection with NC or miR-218 mimics, $n=5$. (F) Expression levels of several factors related to cell proliferation and survival were detected in A549-GLUT1 cells in both NC and mimics groups, $n=5$. * $P<0.05$ and ** $P<0.01$. Data are presented as mean \pm SD. NC, negative control; miR-218, microRNA-218; GLUT1, glucose transporter 1; HK2, hexokinase 2; PFK1, phosphofructokinase-1; G6PD, glucose-6-phosphate dehydrogenase; p-, phosphorylated; t-, total; UTR, untranslated region.

uptake, lactate production and NADPH/NADP⁺ were reduced after transfection with miR-218 mimics in A549-GLUT1 (Fig. 2C-E), suggesting the possibility of other mechanisms.

To explore the signaling pathway involved in glucose metabolism inhibition of miR-218, phosphorylation levels of Akt, ERK1/2, JNK1/2 and NF-κB p65 were detected in A549-GLUT1 transfected with mimic or NC. The present results indicated that the expression level of p-NF-κB p65, but not the other three proteins, was significantly decreased

after transfection with the mimic (Fig. 2F). Therefore, the present results suggested that miR-218 may regulate glucose metabolism by modulating the activity of NF-κB.

miR-218 inhibits glucose metabolism via the NF-κB signaling pathway. To investigate whether the NF-κB pathway mediated glucose metabolism inhibition induced by miR-218, an inhibitor of NF-κB IκBα was stably knocked down by shRNA in A549-GLUT1 cells (Fig. 3A). The acquired cell line was termed




Figure 3. miR-218 inhibits glucose metabolism via the NF- κ B signaling pathway. (A) A549-GLUT1-shI κ B α , a stable GLUT1 overexpressing and I κ B α silencing cell line was constructed and identified by western blotting. (B) Glucose consumption, (C) lactate production and (D) the ratio of NADPH to NADP⁺ were examined in A549-GLUT1 and A549-GLUT1-shI κ B α cells after transfection with NC or miR-218 mimics, n=5. (E) Western blotting was performed to determine the protein expression levels of key enzymes involved in glucose metabolism and (F) the location of GLUT1 on cytomembrane, n=5. *P<0.05. Data are presented as mean \pm SD. NC, negative control; miR-218, microRNA-218; shRNA; short hairpin RNA; shI κ B α , short hairpin I κ B α RNA; GLUT1, glucose transporter 1; p-, phosphorylated; HK2, hexokinase 2; PFK1, phosphofructokinase-1; G6PD, glucose-6-phosphate dehydrogenase; I κ B α , inhibitor of κ B.

'A549-GLUT1-shI κ B α '. After transfection with miR-218 mimics, the A549-GLUT1 cells showed reduced glucose uptake, lactate production and NADPH/NADP⁺ ratio, and vice versa in the A549-GLUT1-shI κ B α (Fig. 3B-D). Similarly, HK-2, PFK1 and G6PD expression levels were decreased by miR-218 in A549-GLUT1 cells, but this effect was diminished in A549-GLUT1-shI κ B α cells (Fig. 3E). Moreover, this was in accordance with results reported in a previous study (24), in which the plasma membrane translocation of GLUT1 was reduced in mimic transfected A549-GLUT1 cells. No

difference was identified between A549-GLUT1-shI κ B α transfected with NC or mimics (Fig. 3F). The present results indicated that glucose metabolism inhibition of miR-218 may be reversed by the activation of the NF- κ B signaling pathway.

The proposed mechanisms of miR-218 regulation of glucose metabolism are shown in Fig. 4. miR-218 reduced the expression levels of GLUT1 directly, but also affected the membrane translocation of GLUT1 and expression levels of key enzymes in glycolysis and PPP pathways indirectly by inhibiting the NF- κ B signaling pathway.




Figure 4. Potential mechanisms of miR-218 inhibition of glucose metabolism. The inhibitory action of miR-218 on glucose metabolism was via reducing the levels of GLUT1 directly and also inactivating the NF- κ B signaling pathway that affects membrane translocation or expression levels of the key enzymes involved in glucose metabolism indirectly. miR-218, microRNA-218; GLUT1, glucose transporter 1; HK2, hexokinase 2; PFK1, phosphofructokinase-1; G6PD, glucose-6-phosphate dehydrogenase; PPP, pentose phosphate pathway.

Discussion

Cancer cells have aberrant expression of miRNAs that are involved in modulating numerous cell signaling pathways (25). Previous studies have shown that miR-218 expression level is significantly reduced in NSCLC (16,17). Recently, miR-218 has been reported as a tumor suppressor in lung cancer cells by regulating the interleukin-6/STAT3 pathway (26). The present study investigated the effect of miR-218 on glucose metabolism and the possible underlying molecular mechanisms in NSCLC cells.

The present results suggested that miR-218 inhibited glucose uptake, glycolysis and PPP. Several rate-limiting enzymes such as GLUT1, HK2, PFK1 and G6PD play crucial roles during these glucose metabolism processes (27). Previous studies have shown that these enzymes are regulated directly or indirectly by miRNAs (28-32). The present results indicated that the expression levels of these enzymes were decrease by miR-218 in NSCLC cell lines. Subsequently, to identify whether the four rate-limiting enzymes were the direct targets of miR-218, a luciferase reporter assay was performed. The present results suggested that GLUT1 was directly modulated by miR-218, but the other enzymes were not. The miR-218 mimics had suppressive effects on glucose uptake, glycolysis and PPP. The present results suggested the presence of an indirect mechanism during the expression of rate-limiting enzymes mediated by miR-218. Previous studies have indicated that Akt, JNK, ERK and NF- κ B signaling pathways play important roles in glucose metabolism regulation (33-40). Therefore, in the present study the phosphorylation of these proteins was detected in A549-GLUT1 cells after transfection with miR-218 mimics. The present results suggested there were no significant differences in the phosphorylation levels of Akt, JNK and ERK, however p-NF- κ B p65 was reduced by miR-218 mimics. The present results indicated that NF- κ B may be responsible for the role of miR-218 in glucose metabolism. To investigate this effect, changes on glucose metabolism in A549-GLUT1-shIkB α cells, A549-shIkB α cells and A549-GLUT1 cells were studied. The present results suggested that glucose uptake, lactate production and NADPH/NADP⁺ ratio in A549-GLUT1-shIkB α cells and A549-shIkB α cells had no significant differences (data not shown). In addition, the present results showed that reduction of IkB α , whose absence results in the activation of NF- κ B (41), inhibited the curb of miR-218 on glucose metabolism. The decreasing effects of miR-218 on membrane translocation of

GLUT1 and expression levels of HK2, PFK1 and G6PD were all reversed by the activation of NF- κ B.

In the present study the hypothesis was investigated *in vitro*, however metabolism in long-term cultivated cell lines may not fully reflect the situation in growing tumors, thus *in vivo* experiments are required to further investigate the effect of miR-218.

In the present study glycolysis and PPP were affected by miR-218 in NSCLC cell lines, thus similar effects based on the present results are expected *in vivo*. Although the present results suggested miR-218 inhibited glucose metabolism by inactivating the NF- κ B signaling pathway in NSCLC cells, the details of the underlying regulatory mechanism still remain unclear. Therefore, the targets of miR-218 in NF- κ B pathway should be investigated in future studies. The reasons for miR-218 expression level change in NSCLC, especially whether it was affected due to low glucose metabolism caused by itself, should be focused on.

In conclusion, the present results suggested miR-218 may inhibit glucose uptake, glycolysis and PPP in NSCLC cells by reducing the expression or membrane translocation of rate-limiting enzymes involved in glucose metabolism, in which NF- κ B played a critical role.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Key Scientific Research Project of Colleges and Universities in Henan Province (grant no. 16A320045) and the Program of Medical Technology Plan in Henan Province (grant no. 2018020790).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XY and QC designed the study. WT, XY and YS performed the experiments. JZ and HW analyzed the data. LW and DL contributed to constructing the engineering A549 cell lines and writing the original draft. WT and QC revised and edited the manuscript. All authors read and approved the final version of the manuscript for publication.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Janssen-Heijnen ML, van Erning FN, De Ruyscher DK, Coebergh JW and Groen HJ: Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. *Ann Oncol* 26: 902-907, 2015.
- Giatromanolaki A, Sivridis E, Arelaki S and Koukourakis MI: Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. *Exp Lung Res* 43: 167-174, 2017.
- Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, *et al*: Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. *Cancer Cell* 24: 213-228, 2013.
- Patra KC and Hay N: The pentose phosphate pathway and cancer. *Trends Biochem Sci* 39: 347-354, 2014.
- Riganti C, Gazzano E, Polimeni M, Aldieri E and Ghigo D: The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fate. *Free Radic Biol Med* 53: 421-436, 2012.
- Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. *Cell Metab* 23: 27-47, 2016.
- Li F, Han X, Li F, Wang R, Wang H, Gao Y, Wang X, Fang Z, Zhang W, Yao S, *et al*: LKB1 Inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. *Cancer Cell* 27: 698-711, 2015.
- Zeng C, Wu Q, Wang J, Yao B, Ma L, Yang Z, Li J and Liu B: NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells. *Free Radic Biol Med* 101: 236-248, 2016.
- Zhou L, Li M, Yu X, Gao F and Li W: Repression of hexokinases II-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non-small cell lung cancer cells. *Int J Biol Sci* 15: 826-837, 2019.
- Ambros V: The functions of animal microRNAs. *Nature* 431: 350-355, 2004.
- Kitamura K, Ohata M, Narata M, Iida M, Ohmori K, Irako M, Nakamura S, Natori H and Sezai Y: Surgical treatment of bilateral spontaneous pneumothorax. *Nihon Kyobu Geka Gakkai Zasshi* 37: 117-122, 1989 (In Japanese).
- Zhang JG, Guo JF, Liu DL, Liu Q and Wang JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. *J Thorac Oncol* 6: 671-678, 2011.
- Wang RT, Xu M, Xu CX, Song ZG and Jin H: Decreased expression of miR216a contributes to non-small-cell lung cancer progression. *Clin Cancer Res* 20: 4705-4716, 2014.
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, *et al*: A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 103: 2257-2261, 2006.
- Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. *Oncogene* 27: 2575-2582, 2008.
- Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, Passmore LH, Bowman RV and Fong KM: MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. *PLoS One* 5: e12560, 2010.
- Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama K, Seki N and Nakagawa M: miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. *Int J Oncol* 39: 13-21, 2011.
- Zeng XJ, Wu YH, Luo M, Cong PG and Yu H: Inhibition of pulmonary carcinoma proliferation or metastasis of miR-218 via down-regulating CDCP1 expression. *Eur Rev Med Pharmacol Sci* 21: 1502-1508, 2017.
- Chiu KL, Kuo TT, Kuok QY, Lin YS, Hua CH, Lin CY, Su PY, Lai LC and Sher YP: ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis. *Sci Rep* 5: 16426, 2015.
- Zarogoulidis P, Petanidis S, Kioseoglou E, Domvri K, Anastakis D and Zarogoulidis K: miR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. *Cell Signal* 27: 1576-1588, 2015.
- Li P, Yang X, Cheng Y, Zhang X, Yang C, Deng X, Li P, Tao J, Yang H, Wei J, *et al*: MicroRNA-218 increases the sensitivity of bladder cancer to cisplatin by targeting Glut1. *Cell Physiol Biochem* 41: 921-932, 2017.
- Yuan X, Tian W, Hua Y, Hu L, Yang J, Xie J, Hu J and Wang F: Rhein enhances the cytotoxicity of effector lymphocytes in colon cancer under hypoxic conditions. *Exp Ther Med* 16: 5350-5358, 2018.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2011.
- Jiang J, Geng G, Yu X, Liu H, Gao J, An H, Cai C, Li N, Shen D, Wu X, *et al*: Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF- κ B/GLUT1 axis. *Oncotarget* 7: 87271-87283, 2016.
- Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 4: 143-159, 2012.
- Yang Y, Ding L, Hu Q, Xia J, Sun J, Wang X, Xiong H, Gurbani D, Li L, Liu Y and Liu A: MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis. *Mol Cancer* 16: 141, 2017.
- Abbaszadeh Z, Çeşmeli S and Biray Avcı Ç: Crucial players in glycolysis: Cancer progress. *Gene* 726: 144158, 2020.
- Yan Y, Yan F and Huang Q: miR-200c inhibited the proliferation of oral squamous cell carcinoma cells by targeting Akt pathway and its downstream Glut1. *Arch Oral Biol* 96: 52-57, 2018.
- Santassusagna S, Moreno I, Navarro A, Muñoz C, Martínez F, Hernández R, Castellano JJ and Monzo M: miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1. *Clin Transl Oncol* 20: 1161-1167, 2018.
- Zhou Y, Zheng X, Lu J, Chen W, Li X and Zhao L: Ginsenoside 20(S)-Rg3 inhibits the warburg effect via modulating DNMT3A/ miR-532-3p/HK2 pathway in ovarian cancer cells. *Cell Physiol Biochem* 45: 2548-2559, 2018.
- Yang Y, Ishak Gabra MB, Hanse EA, Lowman XH, Tran TQ, Li H, Milman N, Liu J, Reid MA, Locasale JW, *et al*: miR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1. *Nat Commun* 10: 809, 2019.
- He C, Yang J, Ding J, Li S, Wu H, Xiong Y, Zhou F, Jiang Y, Teng L and Yang J: Downregulation of glucose-6-phosphate dehydrogenase by microRNA-1 inhibits the growth of pituitary tumor cells. *Oncol Rep* 40: 3533-3542, 2018.
- Yang J, Kou J, Lim JE, Lalonde R and Fukuchi KI: Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway. *Brain Behav Immun* 53: 84-95, 2016.
- Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE and Wolfe MM: Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. *Gastroenterology* 133: 1796-1805, 2007.
- Belgardt BF, Mauer J, Wunderlich FT, Ernst MB, Pal M, Spohn G, Brönneke HS, Brodesser S, Hampel B, Schauss AC and Brüning JC: Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism. *Proc Natl Acad Sci USA* 107: 6028-6033, 2010.
- Xu G, Wang Z, Li Y, Li Z, Tang H, Zhao J, Xiang X, Ding L, Ma L, Yuan F, *et al*: Ghrelin contributes to derangements of glucose metabolism induced by rapamycin in mice. *Diabetologia* 55: 1813-1823, 2012.
- Zhang W, Thompson BJ, Hietakangas V and Cohen SM: MAPK/ERK signaling regulates insulin sensitivity to control glucose metabolism in *Drosophila*. *PLoS Genet* 7: e1002429, 2011.
- Li Q, Li Y, Liang L, Li J, Luo D, Liu Q, Cai S and Li X: Klotho negatively regulated aerobic glycolysis in colorectal cancer via ERK/HIF1 α axis. *Cell Commun Signal* 16: 26, 2018.
- Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, Moretti M, De Smaele E, Beg AA, Tergaonkar V, *et al*: NF- κ B controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. *Nat Cell Biol* 13: 1272-1279, 2011.
- Kawauchi K, Araki K, Tobiume K and Tanaka N: p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. *Nat Cell Biol* 10: 611-618, 2008.
- Gilmore TD: Introduction to NF-kappaB: players, pathways, perspectives. *Oncogene* 25: 6680-6684, 2006.